サイクリン依存キナーゼ阻害剤p19Ink4ddの構造
F Y Luh1, S J Archer, P J Domaille
1Cambridge Centre for Molecular Recognition, Department of Biochemistry, University of Cambridge, UK.
Nature
|November 14, 1997
まとめ
p19Ink4dの構造は,Ink4タンパク質の変異ががん経路をどのように破壊するかを明らかにしています. この発見は,Rb経路を標的とした新しいがん治療法を設計するのに役立ちます.
科学分野:
- バイオケミストリー バイオケミストリー
- 分子生物学は分子生物学である.
- 構造生物学 構造生物学とは
背景:
- 癌は,しばしば腫瘍抑制経路の障害,特にp53とRbを含む経路を伴う.
- Rb経路は細胞サイクル進行を調節し,Rb,サイクリンD1,Cdk4,p16Ink4aなどの重要なタンパク質の変異によってがんではしばしば変化します.
研究 の 目的:
- NMRスペクトロスコーピーを用いてp19Ink4dタンパク質の構造を決定する.
- p16Ink4aの変異がどのように機能の喪失につながるのかを理解するために.
- 治療開発のためのInk4-cyclin-Cdk相互作用のモデルを提案する.
主な方法:
- 核磁共振 (NMR) スペクトロスコピーは,タンパク質の構造を決定する.
- p16Ink4a.a.におけるがん関連変異の分析
- Ink4タンパク質の相互作用の構造モデリング.
主要な成果:
- p19Ink4dのNMR構造が解明されました.
- この研究では,p16Ink4aの機能喪失変異は,しばしばタンパク質の誤折りや不溶性によるものであることが示唆されています.
- Ink4タンパク質とサイクリン-Cdk複合体の相互作用モデルが提案されました.
結論:
- p19Ink4dの決定された構造は,サイクリン依存キナーゼ阻害剤 (CDKI) のInk4ファミリーについての洞察を提供します.
- 変異の構造的影響を理解することは,がん治療において極めて重要です.
- 提案された相互作用モデルは,Rb経路を標的とした新しいがん治療法の設計を導くことができる.
関連する概念動画
01:45Positive Regulator Molecules
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
01:23Negative Regulator Molecules
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
02:39Positive Regulator Molecules
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...